Wayne Koberstein
-
Companies To Watch: Mirum Pharmaceuticals
7/1/2022
Mirum Pharmaceuticals: Two drugs, one FDA approved, together taking on a half-dozen rare liver diseases.
-
Companies To Watch: CinCor Pharma
6/1/2022
CinCor Pharma is uncovering a great potential for combatting treatment-resistant and uncontrolled hypertension.
-
CoCrystal's Co-CEOs
6/1/2022
Most biopharma industry observers would agree the leadership of a company by two co-equal CEOs is a rare thing. But when it does happen, the unusual arrangement offers useful insights.
-
Companies To Watch: Castle Creek Biosciences
5/2/2022
For Castle Creek Biosciences, there are many stakes at play in targeting rare skin, connective tissue, liver, and metabolic disorders.
-
Platforms To Pipelines: Part 2
5/2/2022
In part 2 of this series, we cover each company’s future plans, as well as their leaders’ observations of the platform-to-pipeline space they are effectively expanding, by joining a gathering crowd of companies now entering it.
-
Platforms To Pipelines: Part 1
4/1/2022
To discover why companies go about transforming themselves from technology suppliers into biotherapeutics developers, we spoke with the heads of five companies built upon novel platforms for discovery or development of new biotherapeutics, though at various stages and differences in applied strategies.
-
Companies To Watch: Global Blood Therapeutics
4/1/2022
Global Blood Therapeutics is intertwining science, business, and social missions to make progress against sickle cell disease.
-
Beyond Profits To Biopharma Innovation
4/1/2022
What if, for certain ambitious but traditionally underfunded areas needing innovation, a startup could achieve its ends without the usual for-profit incentives?
-
Companies To Watch: Endevica Bio
3/1/2022
Endevica Bio is developing a new treatment for cachexia, a severe wasting disease critical to patients’ survival in cancer and other conditions.
-
Art Of The Startup — Making New Waves
3/1/2022
As Shoreline’s chairman, CEO, and cofounder, Dr. Kleanthis Xanthopoulos draws on his experience of several decades, starting and running companies that aim to overturn prevailing practices in areas of medicine where practice makes imperfect, with treatments that disappoint patients or prove expensive and impractical for many.